Non-Melanoma Skin Cancers

SKNJCT-003 is expected to enroll up to 60 patients.

The study evaluated the efficacy of AIV001 in superficial, nodular, and mixed BCC tumors.

One of the specific areas of focus will be non-melanoma skin cancer.

Study results were presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.

Learn more about the in-depth topics covered in the September 2023 Frontline Forum BCC management supplement of Dermatology Times.

In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.

In part 3 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

In part 2 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

In part 1 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

Image-Guided Superficial Radiation Therapy kills cancer cells without surgery.

Collaboration between dermatologists and gynecologists can improve patient quality of life and outcomes in vSCC treatment.

Click here to answer this week's poll.

In a murine model, application of PALA in topical fashion led to reductions in tumor grades and numbers.

Reynolds discussed what attendees need to know about using cemiplimab to target their difficult skin cancer patients at the Fall Clinical Dermatology Conference for PAs and NPs.

Principal investigator Jason Luke, MD, discusses what the new data means for melanoma treatment moving forward.

Todd Schlesinger, MD and Emily Ruiz, MD offer advice on forming multidisciplinary relationships for the wholistic study and treatment of basal cell carcinoma.

Emily Ruiz, MD and Todd Schlesinger, MD discuss treatment options for locally advanced basal cell carcinoma, such as immunotherapy and surgery.